LLY stock
-
Eli Lilly Stock Surges After Record Q3 Earnings and Raised Guidance
Eli Lilly delivered a standout third quarter, beating Wall Street forecasts on both earnings and revenue, fueled by soaring demand for diabetes and obesity treatments. The company raised its full-year guidance, signaling strong growth momentum and investor confidence.
-
Eli Lilly Stock Surges Amid FDA Wins and Manufacturing Expansion
Eli Lilly stock jumps as FDA approvals, major contracts, and strategic U.S. investments reshape its financial landscape, signaling a new era for the pharma giant.